IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 301-325 out of 1238.

<< < 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 > >>

Public Release: 9-Sep-2014
Journal of Clinical Investigation
Mesothelial cells promote ovarian cancer metastasis
A new study in the Journal of Clinical Investigation indicates that mesothelial cells actively promote the spread of ovarian cancer.

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 9-Sep-2014
10th Biennial Ovarian Cancer Research Symposium
Olaparib tablet safe in pretreated ovarian cancer patients
An oral tablet form of a PARP inhibitor, olaparib, given in combination with chemotherapy, was safe in heavily pretreated ovarian cancer patients, and patients with BRCA mutations may have a better response compared with those without a BRCA mutation, according to phase Ib clinical trial data presented at the Marsha Rivkin Center for Ovarian Cancer Research-AACR 10th Biennial Ovarian Cancer Research Symposium, held Sept. 8-9.
The Dulien Fund, AstraZeneca

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 8-Sep-2014
Cancer Cell
Notch1 and osteoblasts play role in bone cancer initiation
A new mouse model of osteogenic sarcoma, a potentially deadly form of bone cancer, shows that high levels of Notch1, a gene that helps determine cell fate, can drive osteoblasts, cells that normally lead to bone formation, to become cancerous, said researchers from Baylor College of Medicine in a report in the journal Cancer Cell.
National Institutes of Health, Cancer Prevention and Research Institute of Texas, NIH/Eunice Kennedy Shriver National Institute of Child Health and Human Development, Baylor College of Medicine, Cancer Fighters of Houston

Contact: Glenna Picton
picton@bcm.edu
713-798-4710
Baylor College of Medicine

Public Release: 8-Sep-2014
Oncotarget
Gobbling up poison: A method for killing colon cancer
A new immunotoxin works by getting shuttled into cancer cells, selectively destroying colon cancer, thanks to a quirk of biology.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 8-Sep-2014
European Respiratory Society International Congress
Breath temperature test could identify lung cancer
The temperature of exhaled breath could be used to diagnose lung cancer, according to a new study.

Contact: Lauren Anderson
lauren.anderson@europeanlung.org
142-672-876
European Lung Foundation

Public Release: 8-Sep-2014
Developmental Cell
Popular cancer drug target implicated in cardiovascular defects
UNC School of Medicine researchers have discovered an unlikely relationship between CXCR7 -- a protein implicated in tumor growth and metastasis -- and adrenomedullin -- a hormone involved in cardiovascular health. Deleting CXCR7 allows adrenomedullin to run rampant, triggering the development of an enlarged heart and the overgrowth of the lymphatic vessels that traffic immune cells and fluids throughout the body.
National Institutes of Health, American Heart Association

Contact: Mark Derewicz
mark.derewicz@unchealth.unc.edu
919-923-0959
University of North Carolina Health Care

Public Release: 8-Sep-2014
Urologic Oncology
Watchful waiting isn't right for everyone
African American men are one population that may be harmed by new guidelines that favor observation over treatment of early-stage prostate cancer.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 8-Sep-2014
Cancer Cell
UNC researchers find new genetic target for a different kind of cancer drug
Researchers from the University of North Carolina School of Medicine have discovered that the protein RBM4, a molecule crucial to the process of gene splicing, is drastically decreased in multiple forms of human cancer, including lung and breast cancers. The finding, published today in the journal Cancer Cell, offers a new route toward therapies that can thwart the altered genetic pathways that allow cancer cells to proliferate and spread.
National Cancer Institute

Contact: Mark Derewicz
mark.derewicz@unchealth.unc.edu
919-923-0959
University of North Carolina Health Care

Public Release: 8-Sep-2014
Medical Devices
Bone cancer surgical team sees success in new application of surgical aid
An ortho-oncology team at Dartmouth-Hitchcock Norris Cotton Cancer Center successfully adapted a shoulder surgical aid (the Spider Limb Positioner) to conduct a left hip disarticulation on a melanoma patient as described in a case report published online in Medical Devices.

Contact: Donna Dubuc
Donna.M.Dubuc@Dartmouth.edu
603-653-3615
The Geisel School of Medicine at Dartmouth

Public Release: 8-Sep-2014
Clinical Cancer Research
Novel cancer drug proves safe for leukemia patients
Results of a Phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy. The findings, reported by doctors at Wake Forest Baptist Medical Center, are published in the current online edition of the journal Clinical Cancer Research.
NIH/National Cancer Institute, Doug Coley Foundation for Leukemia Research, Frances P. Tutwiler Fund, MacKay Foundation for Cancer Research, Cornerstone Pharmaceuticals

Contact: Marguerite Beck
marbeck@wakehealth.edu
336-716-2415
Wake Forest Baptist Medical Center

Public Release: 8-Sep-2014
Cancer Cell
Penn team finds ovarian cancer oncogene in 'junk DNA'
A Penn team has mined 'junk DNA' sequences to identify a non-protein-coding RNA whose expression is linked to ovarian cancer.
NIH/National Cancer Institute, Ovarian Cancer Research Fund, Breast Cancer Alliance, Department of Defense, Marsha Rivkin Center for Ovarian Cancer Research, China Scholarship Council

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine

Public Release: 8-Sep-2014
Cancer
Many patients in cancer centers may not experience a dignified death
A new study that surveyed physicians and nurses in hospitals within cancer centers in Germany suggests that many patients there do not experience a dignified death. Published early online in Cancer, a peer- reviewed journal of the American Cancer Society, the study indicates the need for cancer centers to invest more in palliative care services, adequate rooms for dying patients, staff training in end-of-life care, and advance-care-planning standards.

Contact: Evelyn Martinez
sciencenewsroom@wiley.com
201-748-6358
Wiley

Public Release: 7-Sep-2014
54th ICAAC
New antifungal as effective as existing drugs with fewer adverse events
A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.

Contact: Jim Sliwa
jsliwa@asmusa.org
202-942-9297
American Society for Microbiology

Public Release: 7-Sep-2014
Nature Immunology
Dynamic duo takes out the cellular trash
Salk scientists identify how immune cells use two critical receptors to clear dead cells from the body, pointing the way to new autoimmune and cancer therapies.

Contact: Salk Communications
press@salk.edu
Salk Institute

Public Release: 7-Sep-2014
PLOS ONE
Trial shows improved overall survival for patients with liver cancer not amenable to surgery
The mature results from a trial conducted by the Asia-Pacific Hepatocellular Carcinoma Trials Group led by the National Cancer Centre Singapore and Singapore General Hospital have shown that patients who suffer from inoperable advanced hepatocellular carcinoma may have a chance to live significantly longer by using a combined therapy.

Contact: Edwin Yong
yong.c.y@nccs.com.sg
65-623-69465
SingHealth

Public Release: 7-Sep-2014
PLOS ONE
61 percent fall in female genital warts due to free HPV vaccine
General practitioners in Australia are managing 61 percent less cases of genital warts among young women since the introduction of the national human papillomavirus vaccination program, a new study from the University of Sydney reveals.

Contact: Kobi Print
kobi.print@sydney.edu.au
61-481-012-729
University of Sydney

Public Release: 7-Sep-2014
Nature Genetics
Ultraviolet light-induced mutation drives many skin cancers, Stanford researchers find
A genetic mutation caused by ultraviolet light is likely the driving force behind millions of human skin cancers, according to researchers at the Stanford University School of Medicine.
National Institutes of Health, US Veterans Affairs Office of Research and Development

Contact: Krista Conger
kristac@stanford.edu
650-725-5371
Stanford University Medical Center

Public Release: 5-Sep-2014
Oncogene
Combination microRNA therapy shown to suppress non-small-cell lung cancer
New findings show that a combination of two microRNAs suppressed tumor growth in an an animal model of non-small-cell lung cancer.
American Cancer Society, National Institutes of Health, Cancer Prevention & Research Institute of Texas

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center

Public Release: 5-Sep-2014
Cancer Epidemiology, Biomarkers & Prevention
Research finds no association between wearing a bra and breast cancer
A population-based case-control study found no association between bra wearing and increased breast cancer risk among postmenopausal women, according to research published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
NIH/National Cancer Institute

Contact: Jeremy Moore
jeremy.moore@aacr.org
215-446-7109
American Association for Cancer Research

Public Release: 5-Sep-2014
Clinical Cancer Research
New blood test could offer more tailored treatment of ovarian cancer
Researchers from the University of Manchester and The Christie NHS Foundation Trust -- both part of Manchester Cancer Research Centre -- say the test could be developed and used in hospitals within the next few years.

Contact: Alison Barbuti
alison.barbuti@manchester.ac.uk
44-016-127-58383
University of Manchester

Public Release: 5-Sep-2014
Nature Communications
UT Southwestern researchers find new gene mutations for Wilms Tumor
Researchers at UT Southwestern Medical Center and the Gill Center for Cancer and Blood Disorders at Children's Medical Center, Dallas, have made significant progress in defining new genetic causes of Wilms tumor, a type of kidney cancer found only in children.

Contact: Lori Sundeen Soderbergh
lori.soderbergh@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center

Public Release: 5-Sep-2014
Breast Cancer Symposium 2014
Novel immunotherapy vaccine decreases recurrence in HER2 positive breast cancer patients
A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence.

Contact: Laura Sussman
lsussman@mdanderson.org
713-745-2457
University of Texas M. D. Anderson Cancer Center

Public Release: 5-Sep-2014
Journal of Clinical Oncology
Breast cancer specialist reports advance in treatment of triple-negative breast cancer
William M. Sikov, M.D., in the Program in Women's Oncology at Women & Infants Hospital of Rhode Island served as study chair and lead author for a recently-published major national study that could lead to improvements in outcomes for women with triple-negative breast cancer, an aggressive form of the disease that disproportionately affects younger women.

Contact: Susan McDonald
slmcdonald@wihri.org
401-681-2816
Women & Infants Hospital

Public Release: 4-Sep-2014
International Conference of the American Thoracic Society
Chest
A minimally invasive, high-performance intervention for staging lung cancer
Endoscopic biopsy of lymph nodes between the two lungs (mediastinum) is a sensitive and accurate technique that can replace mediastinal surgery for staging lung cancer in patients with potentially resectable tumours.
Canadian Foundation for Innovation, Society of University Surgeons, Fonds de recherche en santé du Québec, Thoracic Surgery Research Foundation of Montreal

Contact: Benjamin Augereau
benjamin.augereau@umontreal.ca
514-343-6796
University of Montreal

Public Release: 4-Sep-2014
SingHealth Duke-NUS Scientific Congress 2014
Study reveals breast surgery as a definitive and safe treatment for elderly patients
A study conducted by National Cancer Centre Singapore has shown that age per se is not a contraindication to breast cancer surgery, and such surgeries may be safely performed for women aged 80 years and above. Led by Dr. Ong Kong Wee, Senior Consultant in the Division of Surgical Oncology, the team consists of Dr. Veronique Tan, Consultant, and Dr. Lee Chee Meng, Resident Doctor. The study explores the safety of breast cancer surgery in women aged 80 years and above.

Contact: Edwin Yong
Edwin.Yong.c.y@nccs.com.sg
65-623-69465
SingHealth

Showing releases 301-325 out of 1238.

<< < 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 > >>

  Search News Releases

     

 

EurekAlert!